Literature DB >> 16473063

Intestinal replacement therapy: timing and indications for referral of patients to an intestinal rehabilitation and transplant program.

Thomas M Fishbein1, Cal S Matsumoto.   

Abstract

Current treatment options for patients suffering from intestinal insufficiency include all forms of intestinal replacement therapy (IRT). Parenteral nutrition has achieved extended success for the majority of patients requiring interval treatment, however, complications leading to failure of this treatment increases with the duration of therapy. There is currently no consensus as to the appropriate timing for transplantation of the intestine or the timing of referral for evaluation at a center experienced with this therapy. Certain patient characteristics warrant evaluation. Those patients with no jejunoileum who have guaranteed lifelong parenteral dependence, both adult and pediatric, should be immediately referred to a transplant center due to the high likelihood of the development of liver disease. Patients with metastatic infectious complications from catheter sepsis, patients with cholestasis seen intermittently with sepsis episodes, patients who are not successfully weaning and who demonstrate progressive thrombocytopenia, and patients with motility disorder experiencing deterioration should also warrant early referral to an intestinal rehabilitation and transplant program. The objective of evaluation is to maximize the opportunities for rehabilitation while not missing the critical window of opportunity for successful transplantation when needed. We favor an aggressive directed approach to rehabilitation, coupled with psychological preparation for both transplantations and other options. Early referral requires trust between the patient, referring physician, and the transplant team to assure that a rush to judgment will not lead to a premature transplant. The current wait list mortality is high, mandating early referral and listing with an approach aimed at maximizing both the success of gastrointestinal support, as well as of transplantation when necessary.

Entities:  

Mesh:

Year:  2006        PMID: 16473063     DOI: 10.1053/j.gastro.2005.12.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

Review 1.  Small bowel transplantation.

Authors:  Stephen J D O'Keefe; Laura Matarese
Journal:  Curr Gastroenterol Rep       Date:  2006-10

2.  Long-term survival in visceral transplant recipients in the new era: A single-center experience.

Authors:  Ahmed M Elsabbagh; Jason Hawksworth; Khalid M Khan; Stuart S Kaufman; Nada A Yazigi; Alexander Kroemer; Coleman Smith; Thomas M Fishbein; Cal S Matsumoto
Journal:  Am J Transplant       Date:  2019-03-26       Impact factor: 8.086

Review 3.  Visceral transplantation in patients with intestinal-failure associated liver disease: Evolving indications, graft selection, and outcomes.

Authors:  Jason S Hawksworth; Chirag S Desai; Khalid M Khan; Stuart S Kaufman; Nada Yazigi; Raffaele Girlanda; Alexander Kroemer; Thomas M Fishbein; Cal S Matsumoto
Journal:  Am J Transplant       Date:  2018-04-06       Impact factor: 8.086

4.  Human gut microbiome adopts an alternative state following small bowel transplantation.

Authors:  Amber L Hartman; Denver M Lough; Dinesh K Barupal; Oliver Fiehn; Thomas Fishbein; Michael Zasloff; Jonathan A Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

5.  Life-threatening risk factors and the role of intestinal transplantation in patients with intestinal failure.

Authors:  Motoshi Wada; Kotaro Nishi; Megumi Nakamura; Hironori Kudo; Satoshi Yamaki; Hideyuki Sasaki; Tomoyuki Sato; Taichi Fukuzawa; Hiromu Tanaka; Takuro Kazama; Shintaro Amae; Masaki Nio
Journal:  Pediatr Surg Int       Date:  2013-11       Impact factor: 1.827

6.  Type 3 innate lymphoid cells are associated with a successful intestinal transplant.

Authors:  Jiman Kang; Katrina Loh; Leonid Belyayev; Priscilla Cha; Mohammed Sadat; Khalid Khan; Yuriy Gusev; Krithika Bhuvaneshwar; Habtom Ressom; Sangeetha Moturi; Jason Kaiser; Jason Hawksworth; Simon C Robson; Cal S Matsumoto; Michael Zasloff; Thomas M Fishbein; Alexander Kroemer
Journal:  Am J Transplant       Date:  2020-07-21       Impact factor: 8.086

Review 7.  Intestinal and multivisceral transplantation.

Authors:  Sérgio Paiva Meira Filho; Bianca Della Guardia; Andréia Silva Evangelista; Celso Eduardo Lourenço Matielo; Douglas Bastos Neves; Fernando Luis Pandullo; Guilherme Eduardo Gonçalves Felga; Jefferson André da Silva Alves; Lilian Amorim Curvelo; Luiz Gustavo Guedes Diaz; Marcela Balbo Rusi; Marcelo de Melo Viveiros; Marcio Dias de Almeida; Marina Gabrielle Epstein; Pamella Tung Pedroso; Paolo Salvalaggio; Roberto Ferreira Meirelles Júnior; Rodrigo Andrey Rocco; Samira Scalso de Almeida; Marcelo Bruno de Rezende
Journal:  Einstein (Sao Paulo)       Date:  2015 Jan-Mar

8.  Rejection of intestinal allotransplants is driven by memory T helper type 17 immunity and responds to infliximab.

Authors:  Alexander Kroemer; Leonid Belyayev; Khalid Khan; Katrina Loh; Jiman Kang; Anju Duttargi; Harmeet Dhani; Mohammed Sadat; Oswaldo Aguirre; Yuriy Gusev; Krithika Bhuvaneshwar; Bhaskar Kallakury; Christopher Cosentino; Brenna Houlihan; Jamie Diaz; Sangeetha Moturi; Nada Yazigi; Stuart Kaufman; Sukanya Subramanian; Jason Hawksworth; Raffaelle Girlanda; Simon C Robson; Cal S Matsumoto; Michael Zasloff; Thomas M Fishbein
Journal:  Am J Transplant       Date:  2020-09-25       Impact factor: 8.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.